Home > Insider Trading > Filing (0001014108-23-000136)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1822791	Clene Inc.	CLNN	Pharmaceutical Preparations (2834)	852828339

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1835544	Chidozie Ugwumba	C/O Symbiosis Capital Management, Llc 609 Sw 8Th Street, Suite 510 Bentonville AR 72712		No	No	Yes	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-06-16	7,500,000	$0.80	13,018,908	No	4	P	Indirect	By Symbiosis II, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Symbiosis II, LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (Right to buy)	Acquisiton	2023-06-16	7,500,000	$0.00	7,500,000	$1.50
Common Stock	Warrants (Right to buy)	Acquisiton	2023-06-16	7,500,000	$0.00	7,500,000	$1.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,500,000	2023-06-16		No	4	A	Indirect
7,500,000	2023-06-16		No	4	A	Indirect

Footnotes

The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.